Quantitative plasma proteomics identifies metallothioneins as a marker of acute-on-chronic liver failure associated acute kidney injury
BackgroundAcute kidney injury (AKI) considerably increases the risk of short-term mortality in acute-on-chronic liver failure (ACLF) but predicting AKI is not possible with existing tools. Our study aimed at de novo discovery of AKI biomarkers in ACLF.MethodsThis observational study had two phases-...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1041230/full |
| _version_ | 1797942661028511744 |
|---|---|
| author | Pragyan Acharya Rohini Saha Javed Ahsan Quadri Saba Sarwar Maroof Ahmad Khan Hem Chandra Sati Nidhi Gauniyal Ahmadullah Shariff Shekhar Swaroop Piyush Pathak Shalimar |
| author_facet | Pragyan Acharya Rohini Saha Javed Ahsan Quadri Saba Sarwar Maroof Ahmad Khan Hem Chandra Sati Nidhi Gauniyal Ahmadullah Shariff Shekhar Swaroop Piyush Pathak Shalimar |
| author_sort | Pragyan Acharya |
| collection | DOAJ |
| description | BackgroundAcute kidney injury (AKI) considerably increases the risk of short-term mortality in acute-on-chronic liver failure (ACLF) but predicting AKI is not possible with existing tools. Our study aimed at de novo discovery of AKI biomarkers in ACLF.MethodsThis observational study had two phases- (A) Discovery phase in which quantitative proteomics was carried-out with day-of-admission plasma from ACLF patients who initially had no-AKI but either progressed to AKI (n=10) or did not (n=9) within 7 days of admission and, (B) Validation phase in which selected biomarkers from the discovery phase were validated by ELISA in a larger set of ACLF plasma samples (n=93) followed by sub-group analyses.ResultsPlasma proteomics revealed 56 differentially expressed proteins in ACLF patients who progressed to AKI vs those who did not. The metallothionein protein-family was upregulated in patients who progressed to AKI and was validated by ELISA as significantly elevated in both- (i) ACLF-AKI vs no-AKI (p-value ≤ 0.0001) and (ii) progression to AKI vs no-progression to AKI (p-value ≤ 0.001). AUROC for AKI vs no-AKI was 0.786 (p-value ≤0.001) and for progression to AKI vs no-progression to AKI was 0.7888 (p-value ≤0.001). Kaplan-Meier analysis revealed that ACLF patients with plasma MT concentration >5.83 ng/mL had a high probability of developing AKI by day 7 (p-value ≤0.0001). High expression of metallothionein genes was found in post-mortem liver biopsies of ACLF patients.ConclusionDay-of-admission measurements of plasma metallothionein can act as predictive biomarkers of AKI in ACLF. |
| first_indexed | 2024-04-10T20:12:10Z |
| format | Article |
| id | doaj.art-3d7b2bef09fd476ab88a92fe8f91ea55 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-10T20:12:10Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-3d7b2bef09fd476ab88a92fe8f91ea552023-01-26T09:57:03ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-01-011310.3389/fimmu.2022.10412301041230Quantitative plasma proteomics identifies metallothioneins as a marker of acute-on-chronic liver failure associated acute kidney injuryPragyan Acharya0Rohini Saha1Javed Ahsan Quadri2Saba Sarwar3Maroof Ahmad Khan4Hem Chandra Sati5Nidhi Gauniyal6Ahmadullah Shariff7Shekhar Swaroop8Piyush Pathak9 Shalimar10Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, IndiaDepartment of Biochemistry, All India Institute of Medical Sciences, New Delhi, IndiaDepartment of Anatomy, All India Institute of Medical Sciences, New Delhi, IndiaDepartment of Anatomy, All India Institute of Medical Sciences, New Delhi, IndiaDepartment of Biostatistics, All India Institute of Medical Sciences, New Delhi, IndiaDepartment of Biostatistics, All India Institute of Medical Sciences, New Delhi, IndiaDepartment of Biochemistry, All India Institute of Medical Sciences, New Delhi, IndiaDepartment of Anatomy, All India Institute of Medical Sciences, New Delhi, IndiaDepartment of Gastroenterology, All India Institute of Medical Sciences, New Delhi, IndiaDepartment of Gastroenterology, All India Institute of Medical Sciences, New Delhi, IndiaDepartment of Gastroenterology, All India Institute of Medical Sciences, New Delhi, IndiaBackgroundAcute kidney injury (AKI) considerably increases the risk of short-term mortality in acute-on-chronic liver failure (ACLF) but predicting AKI is not possible with existing tools. Our study aimed at de novo discovery of AKI biomarkers in ACLF.MethodsThis observational study had two phases- (A) Discovery phase in which quantitative proteomics was carried-out with day-of-admission plasma from ACLF patients who initially had no-AKI but either progressed to AKI (n=10) or did not (n=9) within 7 days of admission and, (B) Validation phase in which selected biomarkers from the discovery phase were validated by ELISA in a larger set of ACLF plasma samples (n=93) followed by sub-group analyses.ResultsPlasma proteomics revealed 56 differentially expressed proteins in ACLF patients who progressed to AKI vs those who did not. The metallothionein protein-family was upregulated in patients who progressed to AKI and was validated by ELISA as significantly elevated in both- (i) ACLF-AKI vs no-AKI (p-value ≤ 0.0001) and (ii) progression to AKI vs no-progression to AKI (p-value ≤ 0.001). AUROC for AKI vs no-AKI was 0.786 (p-value ≤0.001) and for progression to AKI vs no-progression to AKI was 0.7888 (p-value ≤0.001). Kaplan-Meier analysis revealed that ACLF patients with plasma MT concentration >5.83 ng/mL had a high probability of developing AKI by day 7 (p-value ≤0.0001). High expression of metallothionein genes was found in post-mortem liver biopsies of ACLF patients.ConclusionDay-of-admission measurements of plasma metallothionein can act as predictive biomarkers of AKI in ACLF.https://www.frontiersin.org/articles/10.3389/fimmu.2022.1041230/fullACLFAKIproteomicsbiomarkersmetallothioneininflammation |
| spellingShingle | Pragyan Acharya Rohini Saha Javed Ahsan Quadri Saba Sarwar Maroof Ahmad Khan Hem Chandra Sati Nidhi Gauniyal Ahmadullah Shariff Shekhar Swaroop Piyush Pathak Shalimar Quantitative plasma proteomics identifies metallothioneins as a marker of acute-on-chronic liver failure associated acute kidney injury Frontiers in Immunology ACLF AKI proteomics biomarkers metallothionein inflammation |
| title | Quantitative plasma proteomics identifies metallothioneins as a marker of acute-on-chronic liver failure associated acute kidney injury |
| title_full | Quantitative plasma proteomics identifies metallothioneins as a marker of acute-on-chronic liver failure associated acute kidney injury |
| title_fullStr | Quantitative plasma proteomics identifies metallothioneins as a marker of acute-on-chronic liver failure associated acute kidney injury |
| title_full_unstemmed | Quantitative plasma proteomics identifies metallothioneins as a marker of acute-on-chronic liver failure associated acute kidney injury |
| title_short | Quantitative plasma proteomics identifies metallothioneins as a marker of acute-on-chronic liver failure associated acute kidney injury |
| title_sort | quantitative plasma proteomics identifies metallothioneins as a marker of acute on chronic liver failure associated acute kidney injury |
| topic | ACLF AKI proteomics biomarkers metallothionein inflammation |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1041230/full |
| work_keys_str_mv | AT pragyanacharya quantitativeplasmaproteomicsidentifiesmetallothioneinsasamarkerofacuteonchronicliverfailureassociatedacutekidneyinjury AT rohinisaha quantitativeplasmaproteomicsidentifiesmetallothioneinsasamarkerofacuteonchronicliverfailureassociatedacutekidneyinjury AT javedahsanquadri quantitativeplasmaproteomicsidentifiesmetallothioneinsasamarkerofacuteonchronicliverfailureassociatedacutekidneyinjury AT sabasarwar quantitativeplasmaproteomicsidentifiesmetallothioneinsasamarkerofacuteonchronicliverfailureassociatedacutekidneyinjury AT maroofahmadkhan quantitativeplasmaproteomicsidentifiesmetallothioneinsasamarkerofacuteonchronicliverfailureassociatedacutekidneyinjury AT hemchandrasati quantitativeplasmaproteomicsidentifiesmetallothioneinsasamarkerofacuteonchronicliverfailureassociatedacutekidneyinjury AT nidhigauniyal quantitativeplasmaproteomicsidentifiesmetallothioneinsasamarkerofacuteonchronicliverfailureassociatedacutekidneyinjury AT ahmadullahshariff quantitativeplasmaproteomicsidentifiesmetallothioneinsasamarkerofacuteonchronicliverfailureassociatedacutekidneyinjury AT shekharswaroop quantitativeplasmaproteomicsidentifiesmetallothioneinsasamarkerofacuteonchronicliverfailureassociatedacutekidneyinjury AT piyushpathak quantitativeplasmaproteomicsidentifiesmetallothioneinsasamarkerofacuteonchronicliverfailureassociatedacutekidneyinjury AT shalimar quantitativeplasmaproteomicsidentifiesmetallothioneinsasamarkerofacuteonchronicliverfailureassociatedacutekidneyinjury |